Eli Lilly’s diabetes and obesity drug Mounjaro (tirzepatide) demonstrated cardiovascular benefits in a large clinical trial involving more than 13,000 adults with type 2 diabetes and heart disease. In the head-to-head study, Mounjaro matched the heart protection of Lilly’s earlier drug Trulicity (dulaglutide) while delivering greater reductions in A1C and body weight. Patients taking Mounjaro also had a 16% lower risk of death from any cause.
Although the trial did not show statistical superiority in preventing major cardiovascular events like heart attack or stroke, the results support Mounjaro’s expanding role in diabetes care. Detailed findings will be presented at the European Association for the Study of Diabetes conference (EASD 2025), and Lilly plans to seek regulatory approval to add cardiovascular risk reduction to the drug’s label.
GLP-1-based therapies like Mounjaro are showing benefits on multiple fronts—improving blood sugar, supporting weight loss, and reducing risks related to heart and kidney disease. These findings continue to shift how these medicines are used, extending their reach beyond type 2 diabetes and obesity.
A Note About the p value of 0.086 for the Primary Endpoint
On the primary endpoint, the results put Mounjaro and Trulicity on equal footing. While Mounjaro showed an 8% relative reduction in MACE-3 events, the p-value of 0.086 means the difference wasn't statistically significant. Still, it met the non-inferiority threshold, confirming that Mounjaro is at least as effective as Trulicity in reducing cardiovascular risk.
